Sector News

Sorry, Endo. Valeant’s back on top with $173-per-share Salix bid

March 16, 2015
Life sciences
So you thought you could wrestle Salix away from Valeant, Endo? The Canadian pharma has a message for you: Think again.
 
CEO J. Michael Pearson’s deal machine upped its original $158 per share offer for the North Carolina company to $173 per share in cash, or about $15.8 billion, forcing Endo to drop out of the running. With Salix on board with the new price, Valeant expects to close the deal on April 1, it said Monday.
 
While Endo last week offered $175 per share, its bid comprised cash and stock–1.4607 shares of its stock and $45 per Salix share–meaning the deal’s value would fluctuate with Endo’s stock price. Valeant’s counterbid removed that risk, Pearson said in a statement.
 
“This revised offer provides Salix shareholders with all cash at a significant premium and the certainty to close by April 1,” Pearson said in a statement.
 
Of course, that April 1 closing date isn’t exactly “certain”–and Valeant built in some conditions for that exact reason. If Salix shareholders don’t satisfy the minimum tender offer by April 8, Valeant’s price will drop back down to $158 per share, it said.
 
And if Endo had managed to lure Salix away? Valeant raised its breakup fee along with its bid, meaning Salix would have been on the hook for $100 million if it had walked.
 
Valeant’s new proposal builds on its late-February pact to buy Salix, a deal Pearson hailed as a chance to penetrate the fast-growing, “undertreated and underserved” GI market. In inking that accord, Quebec-based Valeant reportedly beat out Shire ($SHPG), rumored to be readying a bid at the time, and Endo, whose advances Salix had already turned down more than once.
 
But Endo–helmed by former Valeant president Rajiv De Silva, an avid dealmaker in his own right–until now refused to go away. Last week, De Silva touted a “substantially superior” transaction that came along with a seat for Salix on the combined company’s board.
 
“While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions,” De Silva said in a statement Monday.
 
Meanwhile, reports say Valeant turned to top shareholders to finance its increased offer, including Bill Ackman’s hedge fund Pershing Square. Late last year, Pearson and Ackman failed in their joint effort to buy Allergan, losing the months-long hostile pursuit to white knight Actavis. Earlier this month, Pershing took a nearly 5% stake in Valeant, saying it has no plans to shake things up there.
 
By Carly Helfand
 

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach